+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 55Years - 84Years
All Genders
ID07095465

52-Week Open-Label Extension Study Evaluating ACP-204 in Adults with Lewy Body Dementia Psychosis

Led by ACADIA Pharmaceuticals Inc. · Updated on 2026-11-04

126

Participants Needed

36

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a 52-week, open-label extension study to evaluate ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This Phase 3 trial aims to assess long-term treatment effects and safety in participants who have previously completed an antecedent ACP-204 study. The study is sponsored by ACADIA Pharmaceuticals Inc. and focuses on adults aged 55 to 84 years. Participants will receive ACP-204 capsules taken orally once daily, starting at 30 mg. The dose may be adjusted during the trial, allowing for increases to 60 mg or reductions back to 30 mg depending on treatment response. The study design includes a single treatment group with no placebo or comparison groups, and treatment is provided openly without masking. Throughout the 52 weeks, participants and their study partners or caregivers will attend all study visits and complete assessments under supervision. Researchers will monitor for treatment-emergent adverse events as the primary outcome. Participants must be able to provide informed consent or assent with consent from a legally authorized representative. Safety and efficacy evaluations will be conducted regularly to ensure participant well-being during the study period.

CONDITIONS

Brief Title

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Research Team

K

Kristin Kidd

B

Becky Howell

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here